**Core tip:** Simultaneous liver kidney transplantation (SLKT) has doubled from 2002-2013. We studied the effect of transplant center volume on survival outcomes. There was a significant survival disadvantage for liver transplant alone (LTA) *vs* SLKT in centers performing 30 SLKT over the study period, although this disadvantage was slightly diminished with increasing center SLKT volume. Therefore, centers with higher transplant volume have a lesser mortality difference in LTA compared to SLKT than those centers with smaller volume.

INTRODUCTION
============

The debate over outcomes of simultaneous liver kidney transplantation (SLKT) *vs* liver transplantation alone (LTA) has intensified since the introduction of Model for End Stage Liver Disease (MELD) into the allocation system for donor livers. An unintentional byproduct of the implementation of the MELD score was an increase in the number of SLKT. From 2002 to 2013, the percentage of SLKT has increased from 4% to 8% of all liver transplants\[[@B1]\], contributing to a shortage of deceased donor kidney grafts for patients on the waitlist for deceased donor kidney transplantation. Since 2007, four guidelines have been proposed for SLKT listing by various societies, including one by the Organ Procurement and Transplant Network (OPTN) and a more recent consensus report by Davis et al\[[@B2]\], Eason et al\[[@B3]\] and Nadim et al\[[@B4]\]. The current recommendations for SLKT include one of the following: (1) Renal replacement therapy (eGFR of 30 mL/min or less) for a minimum of 4-8 wk; (2) proteinuria \> 2 g/d; and (3) biopsy-proven interstitial fibrosis or glomerulosclerosis\[[@B1],[@B4]\].

A recent survey studied variations in practice among liver transplant centers in the United States and found that SLKT listing was influenced by center-size rather than aforementioned guidelines\[[@B5]\]. Of the 88 transplant centers that were surveyed, centers that performed greater than 10 SLKT annually were more likely to use lenient dialysis duration (4 wk *vs* 6 or 8 wk). This variability in center practice may contribute to the significant inconsistencies among numerous studies comparing the outcomes of SLKT *vs* LTA, including patient and graft survival\[[@B6]-[@B9]\]. A 2015 study using the United Network of Organ Sharing (UNOS) database showed LTA outcomes were inferior to SLKT in all patients listed for SLKT\[[@B10]\], while a 2016 re-analysis of UNOS data found the difference in survival was not statistically significant\[[@B11]\]. Similar to large registry analyses, single-center studies have reported mixed findings on the difference in mortality between SLKT and LTA. Many earlier studies showed no difference between outcomes comparing SLKT to LTA\[[@B12]-[@B14]\]; however, a recent single-center study found improved outcomes with SLKT *vs* LTA\[[@B15]\].

Studies have also suggested that larger centers attain more favorable transplant outcomes, even when involving higher-risk recipients or donors\[[@B16],[@B17]\]. Therefore, the disadvantage of performing LTA in patients listed for SLKT (as reported by some prior studies) could be attenuated at the most experienced programs. However, the effect of transplant center volume on outcome differences between SLKT *vs* LTA has not been evaluated. This study examines the transplant center volume as a potential moderating factor in patients initially listed for SLKT. We hypothesized that the survival disadvantage associated with LTA (compared to SLKT) in patients listed for SLKT would be smaller in more experienced centers performing a greater number of SLKT.

MATERIALS AND METHODS
=====================

Data were obtained from the OPTN Standard Transplant Analysis and Research Database\[[@B18]\]. The institutional review board at Nationwide Children's Hospital exempted the study from review (IRB16-01193). The UNOS/OPTN database was queried for all patients ≥ 18 years of age who were listed for SLKT between February 2002 and December 2015 (post-MELD allocation era), and received either SLKT or LTA. Exclusion criteria were prior transplantation, donation from a non-heart beating donor, living donor liver transplant and receipt of a split liver transplant. The primary outcome was patient survival after LTA *vs* SLKT, among patients listed for SLKT.

Descriptive characteristics of patients meeting inclusion criteria were compared according to the type of transplant (LTA *vs* SLKT) using unpaired *t*-tests for continuous data and χ^2^ tests for categorical data. Among patients with known survival time, survival was compared according to transplant type using Kaplan-Meier curves with a log-rank test. Supplemental descriptive statistics and Kaplan-Meier survival curves included stratification of the study sample by tertiles of center SLKT volume, described below. Cases with complete data on covariates were entered in a multivariable Cox proportional hazards model, where the baseline hazard was stratified across transplant centers. In this stratified Cox model, hazard ratios (HRs) represented differences in survival among patients belonging to the same stratum, meaning differences in survival between patients transplanted at the same center. Center volume was primarily defined as the total number of SLKT performed by each center over the study period (2/2002-12/2015). In supplemental analyses, we demonstrate the robustness of our results to using the total number of liver transplants over the study period, or the annual number of SLKT at a given center, as alternative measures of center volume.

In the Cox model, type of transplant (LTA *vs* SLKT) was interacted with continuous center volume to allow the HR of transplant type (*i.e*., estimated difference in survival between LTA and SLKT) to vary according to center volume\[[@B19]\]. The main effect of total center volume was not estimated in the stratified Cox model, as patients transplanted at the same center shared the same value for overall center volume. For model presentation, volume was centered at 30 total SLKT over the study period, approximately corresponding to the median center in the analytic sample, and divided by 10 (*i.e*., a value of 0 indicated 30 SLKT performed over the study period; a value of 1 indicated 40 SLKT performed, and so on). Therefore, the main effect (HR) of transplant type described the difference in survival between LTA and SLKT for a center performing 30 SLKT; while the interaction between transplant type and center volume described how this difference was reduced (if the interaction HR was \< 1) in more experienced centers.

Covariates in the analysis included recipient age, gender, race, etiology of liver disease, diabetes, dialysis, body mass index (BMI), serum creatinine, serum bilirubin, serum albumin, international normalized ratio (INR), Model for End-stage Liver Disease (MELD) score, and estimated glomerular filtration rate (eGFR) according to Modification of Diet in Renal Disease (MDRD) equation. Hepatic encephalopathy on the wait list, year of transplantation, and liver allograft cold ischemia time were also included. Analyses were performed using Stata/IC 13.1 (College Station, TX: StataCorp LP), and *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Study cohort
------------

The analytic sample included 4580 patients listed for SLKT, of whom 393 (9%) received LTA and 4187 (91%) received SLKT. Among these patients, 4573 had known survival time and 4257 had complete data on covariates in the multivariable analysis. There were 121 transplant centers represented in this sample, with a median SLKT volume of 33 over the entire study period \[range: 1-278; interquartile range (IQR): 15-62\]. The median annual SLKT volume was 3 (range: 0-21; IQR: 2-6). The median center liver transplant volume was 561 over the entire study period (range: 4-2696; IQR: 214-986). Overall mortality occurred in 28% of cases (1287/4580). The Kaplan-Meier plot (Figure [1](#F1){ref-type="fig"}) and log-rank test (*P* \< 0.001) demonstrate worse survival of LTA *vs* SLKT recipients among patients initially listed for SLKT. Actuarial 1, 3 and 5 year survival rates among the LTA and SLKT groups were 68% *vs* 87%, 59% *vs* 79%, and 53% *vs* 72%, respectively. Other characteristics are compared between the 2 types of transplant in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of recipients of liver transplant alone or simultaneous liver-kidney transplant

  **Variable[1](#T1FN1){ref-type="table-fn"}**                   **Cases missing data**   **Received LTA (*n* = 393)**   **Received SLK (*n* = 4187)**   ***P* value[2](#T1FN2){ref-type="table-fn"}**
  -------------------------------------------------------------- ------------------------ ------------------------------ ------------------------------- -----------------------------------------------
  Transplant center SLKT volume                                  0                        107 (± 83)                     91 (± 66)                       \< 0.001
  Transplant center LTA volume[3](#T1FN3){ref-type="table-fn"}   0                        1187 (628)                     1111 (627)                      0.024
  Age (yr)                                                       0                        54.2 (± 9.7)                   54.8 (± 9.6)                    0.279
  Male                                                           0                        234 (60%)                      2778 (66%)                      0.007
  Race                                                           0                                                                                       0.079
  White                                                                                   270 (69%)                      2648 (63%)                      
  Black                                                                                   47 (12%)                       639 (15%)                       
  Other                                                                                   76 (19%)                       900 (22%)                       
  Etiology of liver disease                                      0                                                                                       0.004
  Viral                                                                                   114 (29%)                      1182 (28%)                      
  Cryptogenic                                                                             34 (9%)                        330 (8%)                        
  Autoimmune                                                                              31 (8%)                        197 (5%)                        
  NASH                                                                                    43 (11%)                       454 (11%)                       
  Alcoholic                                                                               89 (23%)                       982 (23%)                       
  HCC                                                                                     28 (7%)                        376 (9%)                        
  AHN                                                                                     16 (4%)                        85 (2%)                         
  Other                                                                                   38 (10%)                       581 (14%)                       
  Diabetes                                                       65                       123 (32%)                      1665 (40%)                      0.001
  Dialysis                                                       0                        109 (28%)                      1963 (47%)                      \< 0.001
  BMI (kg/m[2](#T1FN2){ref-type="table-fn"})                     5                        29.0 (± 5.9)                   28.3 (± 5.9)                    0.044
  Serum creatinine (mg/dL)                                       5                        2.8 (± 2.1)                    3.8 (± 2.6)                     \< 0.001
  Bilirubin (mg/dL)                                              5                        8.2 (± 11.7)                   5.7 (± 9.2)                     \< 0.001
  Albumin (mg/dL)                                                6                        3.0 (± 0.8)                    3.0 (± 0.7)                     0.074
  INR                                                            5                        1.9 (± 1.4)                    1.6 (± 0.7)                     \< 0.001
  MELD score                                                     16                       25.6 (± 10.5)                  25.2 (± 8.7)                    0.445
  eGFR                                                           5                        37.5 (± 27.2)                  26.8 (± 22.4)                   \< 0.001
  Hepatic encephalopathy on wait list                            31                       308 (79%)                      2882 (69%)                      \< 0.001
  Liver allograft cold ischemia time                             213                      6.8 (± 2.6)                    6.8 (± 3.5)                     0.706
  Yr of transplant                                               0                        2009 (4)                       2010 (4)                        \< 0.001

Covariates assessed at wait listing, apart from center volume over study period, hepatic encephalopathy on the wait list, liver allograft cold ischemic time, and year of transplant;

*P* value by independent *t*-test for continuous variables and χ^2^ test for categorical variables;

Includes all liver transplants, not limited to LTA among patients listed for SLK. Descriptive characteristics by recipients of liver transplant alone or simultaneous liver-kidney transplant among patients listed for liver and kidney transplant in 2002-2015 (*n* = 4580). SD: Standard deviation; SLK: Simultaneous liver-kidney transplant; LTA: Liver transplant alone; BMI: Body mass index; INR: International normalized ratio; MELD: Model for end-stage liver disease; eGFR: Estimated glomerular filtration rate.

![Post-transplant survival according to type of transplant. Kaplan-Meier post-transplant survival curves, according to type of transplant, among patients initially listed for simultaneous liver-kidney transplant. Actuarial 1, 3 and 5 year survival rates among the LTA and SLKT groups were 68% *vs* 87%, 59% *vs* 79%, and 53% *vs* 72%, respectively. LTA: Liver transplantation alone; SLKT: Simultaneous liver kidney transplantation.](WJH-10-134-g001){#F1}

Survival implication of transplant type
---------------------------------------

The main multivariable stratified Cox model is presented in Table [2](#T2){ref-type="table"}. At a center performing 30 SLKT over the study period, the model estimates a significant survival disadvantage associated with receiving LTA *vs* SLKT (HR = 2.85; 95%CI: 2.21-3.66; *P* \< 0.001). However, a statistically significant modification of this difference was observed as total center SLKT volume increased (interaction HR = 0.97; 95%CI: 0.95-0.99; *P* = 0.010), meaning that the survival disadvantage of LTA *vs* SLKT was attenuated by about 3% for each additional 10 SLKTs performed by a given center over the study period. Based on this model, estimated differences in survival (HR) between LTA and SLKT are plotted across center SLKT volume in Figure [2](#F2){ref-type="fig"}. For example, at a center performing a total of 15 SLKT over the study period (approximately the 25th percentile of centers), the HR of LTA compared to SLKT was 2.98 (95%CI: 2.26-3.92; *P* \< 0.001); while at a center performing a total of 60 SLKT over the study period (approximately the 75^th^ percentile of centers), this HR was reduced to 2.61 (95%CI: 2.11-3.23; *P* \< 0.001).

###### 

Hazard model of survival after liver transplant alone or simultaneous liver-kidney transplant in patients listed for liver and kidney transplant

  **Variable[1](#T2FN1){ref-type="table-fn"}**                   **HR**   **95%CI**      ***P* value**
  -------------------------------------------------------------- -------- -------------- ---------------
  Transplant received                                                                    
  SLK                                                            ref.                    
  LTA                                                            2.85     (2.21, 3.66)   \< 0.001
  Transplant center SLK volume[2](#T2FN2){ref-type="table-fn"}                           
  Interaction with receiving LTA *vs* SLK                        0.97     (0.95, 0.99)   0.010
  Age (yr)                                                       1.01     (1.01, 1.02)   \< 0.001
  Male                                                           1.08     (0.94, 1.24)   0.285
  Race                                                                                   
  White                                                          ref.                    
  Black                                                          1.17     (0.98, 1.39)   0.089
  Other                                                          0.79     (0.66, 0.94)   0.007
  Etiology of liver disease                                                              
  Viral                                                          ref.                    
  Cryptogenic                                                    0.77     (0.61, 0.98)   0.033
  Autoimmune                                                     0.57     (0.41, 0.79)   0.001
  NASH                                                           0.79     (0.63, 1.01)   0.060
  Alcoholic                                                      0.65     (0.54, 0.77)   \< 0.001
  HCC                                                            1.04     (0.83, 1.30)   0.721
  AHN                                                            1.10     (0.75, 1.63)   0.621
  Other                                                          0.77     (0.62, 0.97)   0.024
  Diabetes                                                       1.23     (1.08, 1.40)   0.002
  Dialysis                                                       1.41     (1.19, 1.67)   \< 0.001
  BMI (kg/m[2](#T2FN2){ref-type="table-fn"})                     0.98     (0.97, 0.99)   0.003
  Serum creatinine (mg/dL)                                       0.97     (0.93, 1.01)   0.092
  Bilirubin (mg/dL)                                              1.00     (0.98, 1.01)   0.394
  Albumin (mg/dL)                                                0.88     (0.81, 0.96)   0.004
  INR                                                            0.92     (0.81, 1.05)   0.224
  MELD score                                                     1.00     (0.99, 1.02)   0.661
  eGFR                                                           1.00     (1.00, 1.01)   0.622
  Hepatic encephalopathy on wait list                            1.10     (0.94, 1.28)   0.221
  Liver allograft cold ischemia time                             1.00     (0.98, 1.02)   0.811
  Year of transplant                                             0.98     (0.96, 1.00)   0.107

Covariates assessed at wait listing, apart from center volume over study period, hepatic encephalopathy on the wait list, liver allograft cold ischemic time, and year of transplant;

Total number of SLK performed over study period (2/2002-12/2015), centered at 30 procedures, and divided by 10. Multivariable Cox proportional hazards model, with the baseline hazard stratified on the transplant center, of survival after liver transplant alone or simultaneous liver-kidney transplant among patients listed for liver and kidney transplant in 2002-2015 (*n* = 4257). HR: Hazard ratio; CI: Confidence interval; SLK: Simultaneous liver-kidney transplant; LTA: Liver transplant alone; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma; AHN: Acute hepatic necrosis; BMI: Body mass index; INR: International normalized ratio; MELD: Model for end-stage liver disease; eGFR: Estimated glomerular filtration rate.

![Post-transplant survival according to center volume of simultaneous liver-kidney transplants. Estimated hazard ratios for post-transplant survival, comparing liver transplant alone to simultaneous liver-kidney transplant among patients initially listed for simultaneous liver-kidney transplant, according to center volume of simultaneous liver-kidney transplants. LTA: Liver transplantation alone; SLKT: Simultaneous liver kidney transplantation.](WJH-10-134-g002){#F2}

Our findings were consistent when using total liver transplant center volume as a measure of center expertise; with a survival disadvantage for LTA *vs* SLKT at centers performing approximately the median volume (500) of liver transplants over the study period (HR = 2.89; 95%CI: 2.18-3.83; *P* \< 0.001). This disadvantage was diminished at centers that performed more liver transplants over the study period (interaction HR = 0.97; 95%CI: 0.94-1.00; *P* = 0.027). Despite this statistically significant interaction, a survival disadvantage of LTA *vs* SLKT was predicted for centers of all but the highest total liver transplant volumes (Supplemental Figure 1). Finally, the findings were robust when using a measure of annual, rather than total, SLKT volume (Supplemental Table 1; Supplemental Figure 2). Of note, the main effect of annual center volume in the stratified Cox model was not statistically significant (Supplemental Table 1: HR = 1.00; 95%CI: 0.98-1.02; *P* = 0.940). Therefore, year-to-year fluctuations in SLKT volume within a single center were not associated with survival outcomes of patients originally listed for SLKT.

Survival implication of center volume
-------------------------------------

Supplemental descriptive statistics according to center SLKT volume tertile are presented in Supplemental Table [2](#T2){ref-type="table"}. A log-rank test found no difference in survival among patients in the study cohort according to tertile of center SLKT volume over the study period (*P* = 0.28; Supplemental Figure 3). However, there was marginally less mortality among patients who underwent LTA at larger centers, as illustrated in Supplemental Figure 4 (*P* = 0.05). The smaller survival difference between SLKT *vs* LTA in larger centers may be partially explained by a survival advantage of total center volume for SLKT-listed patients who received LTA.

DISCUSSION
==========

Using a large national registry we found that center volume influenced the disparity in outcomes between LTA and SLKT, among patients initially listed for SLKT. More experienced centers achieved a smaller difference in mortality between the two types of transplant. With limited data investigating how center volume influences outcomes of multi-visceral organ transplantation, our findings suggest a survival disadvantage for LTA *vs* SLKT recipients at low volume centers, which is partially attenuated at higher volume centers. This influence of center volume on the effect of undergoing LTA after being listed for SLKT may also provide some insight into inconsistencies reported in literature on patients listed for SLKT.

While our study showed center volume influenced survival differences between SLKT and LTA, it is important to compare these findings to existing literature investigating this difference. A recent single-center study found improved overall 1- and 5- year survival rates among SLKT recipients compared to LTA recipients (92.3% and 81.6% *vs* 73.3% and 64.3% respectively)\[[@B15]\]. On the other hand, a previous single-center study at a larger center found no 1-year survival advantage in LTA *vs* SLKT recipients\[[@B13]\]. Difference in the size of these centers (according to Scientific Registry of Transplant Recipients data from January 2013-June 2015) are consistent with our findings that the survival disadvantage of LTA among patients listed for SLKT is attenuated at larger centers.

Large database studies have also reached incongruous conclusions. Hmoud et al\[[@B10]\] recently used the UNOS database to show that LTA outcomes were inferior to SLKT in SLKT-listed patients. However, when comparing SLKT recipients to a propensity-matched subgroup of all liver transplant recipients, Sharma et al\[[@B11]\] demonstrated that differences in survival were not clinically significant. By using Cox regression stratified on the transplant center, we attempted to analyze comparable LTA and SLKT recipients (*i.e*., clusters of recipients transplanted at the same center), while preserving the constraint that all LTA patients must have been listed for SLKT. While our results show smaller differences in survival between LTA and SLKT at more experienced centers, there was no expertise threshold above which LTA outcomes were equal to SLKT outcomes in patients initially listed for SLKT.

With increasing rates of SLKT being performed, it is important to consider center expertise as variable influencing transplant outcomes. Existing literature has explored independent influences of center volume on liver transplant outcomes. A 2011 study indicated that the increased center volume led to reduced allograft rejection and improved recipient survival\[[@B16]\]. More recently, 5130 liver transplants were stratified by number of transplants performed, and transplantation at a higher volume center was associated with lower mortality, length of stay, and costs compared to centers performing fewer transplants\[[@B17]\].

We demonstrated a tendency to perform fewer LTA in patients listed for SLKT at larger centers, which could be due to multiple reasons. Compared to smaller centers, larger transplant centers have distinct advantages including a dedicated and experienced organ procurement team and adequate organ transportation and storage facility. Additionally, the increased number of transplants performed may result in a technical advantage and increased experience to adequately address intra-operative and post-procedural complications. The combination of adequate ancillary staff, resources, and patient referrals enable increased SLKT listing and subsequent transplantation at large programs. It is possible that higher LTA mortality at smaller centers was related to patients who could not wait for multi-organ transplantation; and that high volume centers are able to better manage this patient population. These non-measurable factors may influence center specific outcomes, as programs are dependent on outcomes measures to continue to expand their transplant practice.

With the rise in SLKT, there has been an unintentional reduction in available kidney donors candidates afflicted with end-stage renal disease (ESRD). Due to this concomitant single organ donation, experts have suggested stricter criteria for the allocation of two allografts, especially considering limited access to kidneys compared to livers\[[@B6],[@B13],[@B20],[@B21]\]. Recently, Cheng et al\[[@B22]\] outlined an important distinction of utility *vs* urgency based practice, where each SLKT resulted in a reduction of 1-year allograft lifespan to provide sicker patient populations access to dual organ transplantation. Our results indicate that patients listed for SLKT have worse outcomes when only receiving a liver allograft, indicating further discussion regarding standardizing national guidelines for SLKT listing is required. We recognize there is a real need for dual organ transplantation as the OPTN recently proposed a change in SLKT guidelines; however, improving the current allocation system between the ESRD and SLKT population is also needed\[[@B23]-[@B25]\]. Our study suggests when implementing national change, patients listed for SLKT should be evaluated with stricter criteria to ensure individuals listed for SLKT obtain both organs.

The current analysis is limited in several aspects, including the potential exclusion of confounding variables, missing data, and data entry errors. We were unable to assess important variables such as the duration of dialysis or renal impairment, biopsy proven renal interstitial fibrosis, or proteinuria. Although these factors influence the SLKT listing process, our focus was on post-transplant mortality differences between LTA and SLKT groups. Additionally, patients who received a LTA rather than SLKT may have had worsening clinical status, which could inherently bias estimating the difference in survival between the two procedures. Finally, while we used center volume as a measure of expertise, it is important to note it was not possible to assess peri-operative and post-operative management of patients as well as long-term medical management.

In summary, we demonstrated that centers with higher transplant volume achieve smaller difference in mortality with LTA as compared to SLKT among patients initially listed for SLKT. This finding may help reconcile controversy in the literature regarding center size and outcomes of LTA. These findings further demonstrate the need for standardization of SLKT listing guidelines.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

There has been an increase in the number of simultaneous liver kidney transplantation (SLKT) performed over the past decade. Recently, it has been noted that SLKT listing was influenced by center-size rather than by guidelines. Inconsistent outcomes of SLKT *vs* liver transplantation alone (LTA) have been reported.

Research motivation
-------------------

The effect of transplant center volume on outcome differences between SLKT *vs* LTA has not been evaluated. As such, the authors examined transplant center volume as a potential moderating factor in patients initially listed for SLKT.

Research objectives
-------------------

The authors hypothesized that the survival disadvantage associated with LTA (compared to SLKT) in patients listed for SLKT would be smaller in more experienced centers performing a greater number of SLKT.

Research methods
----------------

The United Network of Organ Sharing database was queried for patients ≥ 18 years of age listed for SLKT between February 2002 and December 2015. Post-transplant survival was evaluated using stratified Cox regression with interaction between transplant type (LTA *vs* SLKT) and center volume.

Research results
----------------

Overall, 393 of 4580 patients (9%) listed for SLKT underwent LTA. Mortality was higher among LTA recipients (180/393, 46%) than SLKT recipients (1107/4187, 26%). The Cox model predicted a significant survival disadvantage for patients receiving LTA *vs* SLKT (HR: 2.85; 95%CI: 2.21-3.66) in centers performing 30 SLKT over the study period. This disadvantage was modestly attenuated as center SLKT volume increased, with a 3% reduction (HR: 0.97; 95%CI: 0.95-0.99) for every 10 SLKs performed.

Research conclusions
--------------------

LTA is associated with increased mortality among patients listed for SLKT. This difference is modestly attenuated at more experienced centers and may explain inconsistencies between smaller-center and larger registry-wide studies comparing SLKT and LTA outcomes.

Research perspectives
---------------------

The findings of this study may help to reconcile the current controversy regarding center size and outcomes of LTA. Future research should focus on the apparent need for standardization of SLKT listing guidelines.
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